Delivered $450 million in full-year net sales for 2025, establishing XDEMVY as a breakout therapeutic and the company as a leader in eye care. Achieved profitability at the product line level for XDEMVY, providing financial flexibility to reinvest in high-return growth drivers. Expanded the addressable market focus beyond the initial 9 million patients to the full 25 million Americans with Demodex blepharitis as screening becomes routine. Attributed commercial success to a 'repeatable playbook' that ...

Core Viewpoint - The market anticipates Mirum Pharmaceuticals, Inc. (MIRM) to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Earnings Expectations - The consensus EPS estimate for Mirum Pharmaceuticals is $0.02 per share, reflecting a year-over-year increase of +104.1% [3] - Expected revenues are projected to be $141.27 million, which is an increase of 42.1% compared to the same quarter last year [3] Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 50.88% higher, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Mirum Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +675.00% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Mirum Pharmaceuticals currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Mirum Pharmaceuticals was expected to post a loss of $0.1 per share but instead reported earnings of $0.05, resulting in a surprise of +150.00% [13] - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14] Industry Context - Another company in the same industry, Tarsus Pharmaceuticals, Inc. (TARS), is expected to report a loss of $0.19 per share, with revenues projected at $144.96 million, reflecting a year-over-year increase of 118.3% [18][19] - Tarsus Pharmaceuticals has an Earnings ESP of +136.84% and a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [20]

Core Insights - Cigna Group (CI) is expected to report fourth-quarter 2025 results on February 5, 2026, with earnings estimated at $7.87 per share and revenues of $69.9 billion, reflecting an 18.5% year-over-year increase in earnings and a 6.5% increase in revenues [1][2] Financial Performance - For the full year 2025, Cigna's revenue is projected at $270 billion, indicating a 9.3% year-over-year growth, while the EPS consensus is $29.63, signaling an 8.4% growth year-over-year [2] - Cigna has beaten earnings estimates in three of the last four quarters, with an average surprise of negative 1.8% [2] Earnings Predictions - The current Earnings ESP for Cigna is 0.00% with a Zacks Rank of 3 (Hold), indicating uncertainty regarding an earnings beat this quarter [3] - The consensus estimate for pharmacy revenues shows a 12.2% improvement year-over-year, while fees and other revenues are expected to grow by 12.1% [4] Segment Performance - Revenues from the Evernorth Health Services segment are projected at $59.2 billion, reflecting a 10.1% growth from the previous year, with pre-tax adjusted income expected to increase by 1.9% [5] - The medical care ratio (MCR) is estimated at 87.21%, down from 87.90% a year ago [5] Challenges - Cigna is facing a projected 22.2% decrease in premiums year-over-year and a decline in total medical customers from 19.1 million to 18.1 million [7] - A decline in net investment income is anticipated, with a consensus estimate suggesting a 5.1% year-over-year decrease [8]

Core Insights - BioMarin Pharmaceutical (BMRN) has a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to Tarsus Pharmaceuticals, Inc. (TARS), which has a Zacks Rank of 3 (Hold) [3] - Value investors utilize various metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Valuation Metrics - BMRN has a forward P/E ratio of 10.82, significantly lower than TARS's forward P/E of 71.71, suggesting BMRN is more attractively priced [5] - The PEG ratio for BMRN is 0.54, while TARS has a PEG ratio of 1.26, indicating BMRN's expected earnings growth is more favorable [5] - BMRN's P/B ratio stands at 1.83, compared to TARS's P/B of 9.57, further highlighting BMRN's relative valuation strength [6] Value Grades - BMRN holds a Value grade of A, while TARS has a Value grade of D, indicating BMRN is viewed as the superior value investment based on earnings outlook and valuation metrics [6]

Core Insights - The State Street SPDR S&P Pharmaceuticals ETF (XPH) is designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, launched on June 19, 2006 [1] - The ETF has gained popularity among retail and institutional investors due to its low costs, transparency, flexibility, and tax efficiency [1][2] Fund Overview - Sponsored by State Street Investment Management, XPH has assets exceeding $208.47 million, categorizing it as an average-sized ETF [3] - The ETF aims to match the performance of the S&P Pharmaceuticals Select Industry Index before fees and expenses [3][4] Cost Structure - XPH has annual operating expenses of 0.35%, making it one of the least expensive options in its category [5] - The ETF offers a 12-month trailing dividend yield of 0.92% [5] Sector Exposure and Holdings - The ETF is heavily allocated in the Healthcare sector, with approximately 99.9% of its portfolio dedicated to this area [6] - Crinetics Pharmaceuticals Inc (CRNX) constitutes about 3.31% of total assets, with the top 10 holdings representing around 29.03% of total assets under management [7] Performance Metrics - As of November 28, 2025, XPH has gained approximately 28.24% and is up about 19.46% year-to-date [8] - The ETF has traded between $36.65 and $54.78 over the past 52 weeks, with a beta of 0.61 and a standard deviation of 18.94% for the trailing three-year period [8] Alternatives - XPH carries a Zacks ETF Rank of 3 (Hold), indicating it is a sufficient option for investors seeking exposure to the Health Care ETFs area [10] - Other alternatives include iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH), with assets of $779.75 million and $1.19 billion respectively [11]

Core Insights - The State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on June 19, 2006, and provides broad exposure to the Health Care ETFs category [1] - The fund is designed to match the performance of the S&P Pharmaceuticals Select Industry Index, which represents the pharmaceuticals sub-industry of the S&P Total Markets Index [5][6] Fund Overview - The fund is sponsored by State Street Investment Management and has accumulated over $211.21 million in assets, categorizing it as an average-sized ETF in the Health Care sector [5] - The ETF has annual operating expenses of 0.35% and a 12-month trailing dividend yield of 0.92% [7] Sector Exposure and Holdings - The fund has a significant allocation to the Healthcare sector, representing 99.9% of the portfolio [8] - Crinetics Pharmaceuticals Inc (CRNX) constitutes approximately 3.31% of the fund's total assets, with the top 10 holdings accounting for about 29.03% of total assets under management [9] Performance Metrics - Year-to-date, the ETF has increased by approximately 28.24% and is up about 20.74% over the last 12 months as of November 27, 2025 [11] - The fund has a beta of 0.61 and a standard deviation of 18.96% over the trailing three-year period, indicating a higher risk profile [11] Alternatives - Other ETFs in the pharmaceuticals space include iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH), with assets of $723.74 million and $1.2 billion respectively [13] - IHE has an expense ratio of 0.38% while PPH charges 0.36%, presenting alternatives for investors seeking lower-cost options [13]

Core Insights - The article highlights stocks reaching new 52-week highs, indicating market recognition of strong fundamentals and potential catalysts for growth [1][2]. Company Summaries Cogent Biosciences Inc. (COGT) - Cogent Biosciences plans to file its first New Drug Application for Bezuclastinib by the end of 2025, targeting non-advanced systemic mastocytosis [3]. - A phase III trial comparing Bezuclastinib with Sutent is ongoing, with results expected in the second half of 2025 [4]. - The stock reached a 52-week high of $16.99, up from $7.25 when last featured [5]. Assembly Biosciences Inc. (ASMB) - Assembly Biosciences is advancing four key development programs, with ABI-5366 expected to enter phase 2 studies in mid-2026 [6]. - Interim data for ABI-1179 is anticipated this fall, while ABI-6250 is in a phase 1a trial [7]. - The stock hit a 52-week high of $28, up from $14.53 when last featured [8]. Compass Therapeutics Inc. (CMPX) - Compass Therapeutics is conducting a phase 2/3 study of Tovecimig for advanced biliary tract cancer, with analyses of secondary endpoints expected in Q1 2026 [9][10]. - The stock reached a 52-week high of $4.39, up from $2.91 when last featured [11]. NewAmsterdam Pharma Company N.V. (NAMS) - NewAmsterdam Pharma is developing Obicetrapib as a cholesterol-lowering therapy, with positive data from the BROADWAY trial [12][13]. - The company has completed two additional phase III trials and submitted marketing applications to the EMA [16]. - The stock reached a 52-week high of $39.76, up from $21.56 when last featured [17]. Mineralys Therapeutics Inc. (MLYS) - Mineralys is developing Lorundrostat for uncontrolled hypertension, with a pivotal phase III trial achieving its primary endpoint [19]. - A phase II trial for overweight participants with OSA is ongoing, with topline results expected in 1H 2026 [20]. - The stock hit a 52-week high of $43.88, up from $10.34 when last featured [20]. Kymera Therapeutics Inc. (KYMR) - Kymera is set to report data from its phase I trial of KT-621 this quarter, with phase 2b studies planned for late 2025 and early 2026 [21][22]. - The stock reached a 52-week high of $60, up from $40 when last featured [22]. Insmed Inc. (INSM) - Insmed has two approved drugs and is conducting a phase 3 trial of Arikayce, with topline results expected in 1H 2026 [24][25]. - The stock hit a high of $166.54, up from $76.54 when last featured [26]. Adaptive Biotechnologies Corp. (ADPT) - Adaptive Biotechnologies expects MRD revenue between $190 million and $200 million for 2025, up from $145.5 million in 2024 [28][29]. - The stock reached a 52-week high of $15.94, up from $9.80 when last featured [29]. BridgeBio Pharma Inc. (BBIO) - BridgeBio has upcoming topline results from the FORTIFY and CALIBRATE studies expected in Fall 2025 [30]. - The stock reached a 3-year high of $56.24, up from $25.10 when last featured [31]. Tarsus Pharmaceuticals Inc. (TARS) - Tarsus reported strong sales for Xdemvy, with Q2 2025 sales of $102.7 million, compared to $40.8 million in Q2 2024 [32]. - The stock hit an all-time high of $70.15, up from $25.01 when last featured [34]. Palvella Therapeutics Inc. (PVLA) - Palvella's QTORIN is under development for various skin diseases, with a phase 2 trial expected to report data in mid-December 2025 [35][36]. - The stock reached a 52-week high of $76.76, up from $25 when last featured [36]. Merus N.V. (MRUS) - Merus agreed to be acquired by Genmab for $97 per share, with the deal expected to close in early Q1 2026 [37]. - The stock was at $39.71 when last featured [39]. Nephros Inc. (NEPH) - Nephros reported net revenue of $4.4 million for Q2 2025, marking its third consecutive quarter of profitability [40][41]. - The stock hit a 52-week high of $5.98, up from $2.93 when last featured [42].

Company Overview - Vir Biotechnology, Inc. (VIR) shares increased by 6.9% to close at $6.05, supported by high trading volume, and have gained 8% over the past four weeks [1] - The rise in stock price is linked to positive investor sentiment regarding the company's late-stage pipeline candidate, tobevibart, aimed at treating chronic hepatitis delta [1] Financial Performance - The company is projected to report a quarterly loss of $0.70 per share, reflecting a year-over-year increase of 55.1% [2] - Expected revenues are $7.04 million, which is a significant increase of 195.6% compared to the same quarter last year [2] Earnings Estimates - The consensus EPS estimate for Vir Biotechnology has remained unchanged over the last 30 days, indicating stability in earnings expectations [3] - A stock's price typically does not continue to rise without trends in earnings estimate revisions, suggesting the need for monitoring future developments for VIR [3] Industry Context - Vir Biotechnology is categorized under the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Tarsus Pharmaceuticals, Inc. (TARS) [4] - Tarsus Pharmaceuticals has seen a 1.9% increase in its stock price, closing at $69.75, with a notable return of 21.1% over the past month [4] Comparative Analysis - Tarsus Pharmaceuticals has a consensus EPS estimate of -$0.38, which is a 37.7% improvement from the previous year [5] - Tarsus currently holds a Zacks Rank of 4 (Sell), contrasting with Vir Biotechnology's Zacks Rank of 3 (Hold) [4][5]

Core Insights - The biotech industry is characterized by high risks and potential rewards, where positive news can significantly impact share prices and company viability [1] Group 1: Boston Scientific - Boston Scientific Corp. specializes in medical devices for gastrointestinal and pulmonary conditions, with recent FDA safety alerts affecting its heart devices leading to a temporary dip in share price [2][3] - The company reported a 17% year-over-year (YOY) organic sales increase, with a notable 28% growth for its Watchman device, surpassing analyst expectations for both revenue and earnings [4][5] - Analysts are bullish on Boston Scientific, with 24 out of 26 rating it a Buy and a price target suggesting over 10% upside potential [5] Group 2: Arcutis Biotherapeutics - Arcutis Biotherapeutics focuses on dermatological treatments, with its product ZORYVE driving a remarkable 164% YOY growth in product sales for the latest quarter [6][7] - The FDA approved ZORYVE foam for additional uses, expanding its market reach, and the company anticipates further regulatory decisions later in the year [7][8] - Despite facing competition, Arcutis has a strong pipeline and is rated a Buy by six out of seven analysts, with a potential upside of 24% [8] Group 3: Tarsus Pharmaceuticals - Tarsus Pharmaceuticals specializes in eye care, reporting a net sales beat of nearly $103 million, driven by its Demodex treatment XDEMVY [10][11] - The company is conducting a promising Phase II study for its TP-04 treatment for ocular rosacea, contributing to a positive outlook among analysts [11] - Tarsus shares have increased about 4% year-to-date, with analysts indicating over 16% upside potential [11]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 瞼緣炎是一種常見的眼科疾病。蠕形蟎瞼緣炎是蠕形蟎感染瞼緣所致的慢性炎性反應性 疾病，約佔所有瞼緣炎病例的三分之二以上，主要累及瞼緣皮膚、睫毛囊和腺體以及瞼 板腺，以眼瞼搔癢、眼異物感、眼幹、瞼緣充血、鱗屑及睫毛根部袖套狀分泌物等為典 型臨床表現，嚴重者可引起結膜及角膜併發症。中國目前有超過 4,000 萬蠕形蟎瞼緣炎 患者，且並未有針對蠕形蟎瞼緣炎的藥物上市，臨床上急需一款起效快且可直接針對病 因的安全有效的治療藥物，GPN01768 則有望填補該臨床空白。 此外，蠕形蟎也是瞼板腺功能障礙的危險因素之一，蠕形蟎導致的瞼板腺功能障礙患者 常出現眼瞼邊緣發炎和視力模糊，並可能導致瞼板腺堵塞和/或瞼脂液分泌的減少，若 不及時接受治療，可能會導致淚膜永久性改變 ...